Neutralization of PD-L2 is Essential for Overcoming Immune Checkpoint Blockade Resistance in Ovarian Cancer

PURPOSE: Ovarian cancer represents a major clinical hurdle for immune checkpoint blockade (ICB), with reported low patient response rates. We found that the immune checkpoint ligand PD-L2 is robustly expressed in patient samples of ovarian cancers and other malignancies exhibiting suboptimal respons...

Descripción completa

Detalles Bibliográficos
Autores principales: Miao, Yu Rebecca, Thakkar, Kaushik N., Qian, Jin, Kariolis, Mihalis S., Huang, Wei, Nandagopal, Saravanan, Yang, Teddy Tat Chi, Diep, Anh N., Cherf, Gerald Maxwell, Xu, Yu, Moon, Eui Jung, Xiao, Yiren, Alemany, Haizea, Li, Tiane, Yu, Wenhua, Wei, Bo, Rankin, Erinn B., Giaccia, Amato J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Translational Cancer Mechanisms and Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8338886/
https://www.ncbi.nlm.nih.gov/pubmed/34011561
http://dx.doi.org/10.1158/1078-0432.CCR-20-0482

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8338886/
https://www.ncbi.nlm.nih.gov/pubmed/34011561
http://dx.doi.org/10.1158/1078-0432.CCR-20-0482

Ejemplares similares